Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience.

Guerrieri SLazzarin SZanetta CNozzolillo AFilippi MMoiola L

Published in: Journal of neurology (2021)

Our initial real-life experience suggests a variable antibody production in MS patients receiving these DMTs. At present, there are no sufficient data to do not recommend anti-SARS-CoV-2 vaccine in these patients.

Keyphrases

multiple sclerosis
sars cov
end stage renal disease
chronic kidney disease
ejection fraction
mass spectrometry
prognostic factors
white matter
patient reported outcomes
ms ms
machine learning
deep learning
patient reported